GLP-1 receptor agonists and tirzepatide gall bladder-related AEs

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-023-36401-0
中图分类号
学科分类号
摘要
引用
收藏
页码:4 / 4
相关论文
共 50 条
  • [41] GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
    Bezin, Julien
    Gouverneur, Amandine
    Penichon, Marine
    Mathieu, Clement
    Garrel, Renaud
    Hillaire-Buys, Dominique
    Pariente, Antoine
    Faillie, Jean-Luc
    DIABETES CARE, 2023, 46 (02) : 384 - 390
  • [42] Mapping the effectiveness and risks of GLP-1 receptor agonists
    Yan Xie
    Taeyoung Choi
    Ziyad Al-Aly
    Nature Medicine, 2025, 31 (3) : 951 - 962
  • [43] Why are GLP-1 receptor agonists in short supply?
    Bailey, Clifford J.
    BRITISH JOURNAL OF DIABETES, 2022, 22 (02): : 72 - 72
  • [44] GLP-1 Receptor Agonists in Diabetic Kidney Disease
    Michos, Erin D.
    Tuttle, Katherine R.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 16 (10): : 1578 - 1580
  • [45] GLP-1 receptor agonists: differentiation within the class
    Taylor, Simeon I.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (02): : 83 - 85
  • [46] GLP-1 receptor agonists, carotid atherosclerosis and retinopathy
    Rizzo, Manfredi
    Nikolic, Dragana
    Di Pace, Francesco
    Papanas, Nikolaos
    Montano, Nicola
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1163 - 1165
  • [47] GLP-1 receptor agonists and the risk of thyroid cancer
    Gouverneur, A.
    Penichon, M.
    Bezin, J.
    Garrel, R.
    Hillaire-Buys, D.
    Pariente, A.
    Faillie, J. L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 105 - 105
  • [50] The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia
    Novodvorsky, Peter
    Haluzik, Martin
    CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (01) : 13 - 21